Cargando…
P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428990/ http://dx.doi.org/10.1097/01.HS9.0000847212.00073.29 |
| _version_ | 1784779292674097152 |
|---|---|
| author | Gregory, G. Timmerman, J. Lavie, D. Borchmann, P. Herrera, A. F. Minuk, L. Vucinic, V. Armand, P. Avigdor, A. Gasiorowski, R. Herishanu, Y. Keane, C. Kuruvilla, J. Palcza, J. Pillai, P. Marinello, P. Johnson, N. A. |
| author_facet | Gregory, G. Timmerman, J. Lavie, D. Borchmann, P. Herrera, A. F. Minuk, L. Vucinic, V. Armand, P. Avigdor, A. Gasiorowski, R. Herishanu, Y. Keane, C. Kuruvilla, J. Palcza, J. Pillai, P. Marinello, P. Johnson, N. A. |
| author_sort | Gregory, G. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9428990 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94289902022-08-31 P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY Gregory, G. Timmerman, J. Lavie, D. Borchmann, P. Herrera, A. F. Minuk, L. Vucinic, V. Armand, P. Avigdor, A. Gasiorowski, R. Herishanu, Y. Keane, C. Kuruvilla, J. Palcza, J. Pillai, P. Marinello, P. Johnson, N. A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9428990/ http://dx.doi.org/10.1097/01.HS9.0000847212.00073.29 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Gregory, G. Timmerman, J. Lavie, D. Borchmann, P. Herrera, A. F. Minuk, L. Vucinic, V. Armand, P. Avigdor, A. Gasiorowski, R. Herishanu, Y. Keane, C. Kuruvilla, J. Palcza, J. Pillai, P. Marinello, P. Johnson, N. A. P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY |
| title | P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_full | P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_fullStr | P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_full_unstemmed | P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_short | P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_sort | p1086: favezelimab (anti–lag-3) and pembrolizumab co-blockade in anti–pd-1–naive patients with relapsed or refractory classical hodgkin lymphoma: an open-label phase 1/2 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428990/ http://dx.doi.org/10.1097/01.HS9.0000847212.00073.29 |
| work_keys_str_mv | AT gregoryg p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT timmermanj p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT lavied p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT borchmannp p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT herreraaf p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT minukl p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT vucinicv p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT armandp p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT avigdora p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT gasiorowskir p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT herishanuy p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT keanec p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT kuruvillaj p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT palczaj p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT pillaip p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT marinellop p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study AT johnsonna p1086favezelimabantilag3andpembrolizumabcoblockadeinantipd1naivepatientswithrelapsedorrefractoryclassicalhodgkinlymphomaanopenlabelphase12study |